between WAF-1 positivity and gender, site of origin of the MCC, previous p53 positivity, or recurrence/survival.
This study suggests that wild-type p53 is a transient protein in MCC. A similar lack of association between wild-type p53 or WAF-1 RNA and prognosis has been described for childhood acute lymphoblastic leukemia (5) and prostatic adenocarcinoma (1). However, some investigators describe a poor prognosis associated with wild-type p53 in patients with olfactory neuroblastoma (6), while others report various outcomes from the introduction of wild-type p53 into pancreatic carcinoma cells (4) .
The presence of mutant p53 protein in neoplasms generally suggests a poor prognosis for that class of tumor. In contrast, wild-type p53 protein appears to function diversely in different types of tumors. So, specific study of wild-type p53 may be needed to determine if this antigen could provide prognostic information for a given type of neoplasm. 
